GIBSON DUNN

Gibson Dunn Advises Arrowhead Pharmaceuticals on Establishing “At the Market” Facility for Sale of up to $500 Million of Common Stock

Firm News | December 11, 2025

Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on establishing an "at the market" facility for the sale of up to $500 million of its common stock. Arrowhead is a biotechnology company developing medicines that treat intractable diseases by silencing the genes that cause them.

Gibson Dunn regularly advises life sciences companies on capital markets transactions, including at-the-market offerings and equity financings.

The Gibson Dunn team included Ryan Murr, Melanie Neary, and Lauren Navarro.

Related Capabilities

Capital Markets

Life Sciences

Related People

Ryan A. Murr

Melanie E. Neary

Lauren Navarro

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**